Tuberculosis and Respiratory Diseases

  • 제78권2호
  • /
  • Pages.92-98
  • /
  • 2015
  • /
  • 1738-3536(pISSN)
  • /
  • 2005-6184(eISSN)
대한결핵및호흡기학회 (The Korean Academy of Tuberculosis and Respiratory Diseases)
권호 표지
DOI QR코드

DOI QR Code

Seven-Day Continuous Abstinence Rate from Smoking at 1, 2, or 3 Years after the Use of Varenicline

  • Kim, Jin Se (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Jang, Ju Young (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Park, Eun Hye (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Lee, Joo Young (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Gu, Kang Mo (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Jung, Jae Woo (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Choi, Jae Chol (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Shin, Jong Wook (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Park, In Won (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Choi, Byoung Whui (Department of Internal Medicine, Chung-Ang University College of Medicine) ;
  • Kim, Jae Yeol (Department of Internal Medicine, Chung-Ang University College of Medicine)
  • 투고 : 2014.02.20
  • 심사 : 2014.05.21
  • 발행 : 2015.02.28
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Background: Varenicline, a selective partial agonist/antagonist of the ${\alpha}4{\beta}2$ nicotinic receptor, has proven effectiveness for smoking cessation by several randomized, controlled trials. Because few studies have evaluated the long-term efficacy of varenicline, we tried to evaluate the smoking status of varenicline users up to 3 years after the initial prescription of the drug. Methods: We interviewed varenicline users who were prescribed the drug from June 2007 to May 2010 by telephone, from June 2010 to May 2011. Results: One-hundred and thirty-three of 250 varenicline users (53.2%) were available for the survey. Seven-day continuous abstinence from smoking was adhered to by 17 of 39 respondents (43.6%) at 1 year, and 11 of 36 (30.6%) and 19 of 58 (32.8%) at 2 and 3 years since the first use of varenicline, respectively. Compared to current smokers, successful quitters were older (55.0 years vs. 49.9 years, p=0.01), had better compliance to the 12-week course (27.7 vs. 9.3%, p=0.01), and had taken varenicline longer (10.1 vs. 5.9 weeks, p=0.01). Fifty-four of 71 current smokers (76.1%) were willing to stop smoking in the near future. The preferred ways to cease smoking were will-power (48.1%), varenicline (25.9%), nicotine replacement therapy (11.1%), and others (14.9%). Conclusion: Smokers should be encouraged to stick to the proven way for recommended period of time for successful cessation of smoking.

키워드

참고문헌

  1. Coe JW, Brooks PR, Wirtz MC, Bashore CG, Bianco KE, Vetelino MG, et al. 3,5-Bicyclic aryl piperidines: a novel class of alpha4beta2 neuronal nicotinic receptor partial agonists for smoking cessation. Bioorg Med Chem Lett 2005;15:4889-97. https://doi.org/10.1016/j.bmcl.2005.08.035
  2. Hays JT, Ebbert JO. Varenicline for tobacco dependence. N Engl J Med 2008;359:2018-24. https://doi.org/10.1056/NEJMct0800146
  3. Gonzales D, Rennard SI, Nides M, Oncken C, Azoulay S, Billing CB, et al. Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. JAMA 2006;296:47-55. https://doi.org/10.1001/jama.296.1.47
  4. Nakamura M, Oshima A, Fujimoto Y, Maruyama N, Ishibashi T, Reeves KR. Efficacy and tolerability of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, in a 12-week, randomized, placebo-controlled, dose-response study with 40-week follow-up for smoking cessation in Japanese smokers. Clin Ther 2007;29:1040-56. https://doi.org/10.1016/j.clinthera.2007.06.012
  5. Tsai ST, Cho HJ, Cheng HS, Kim CH, Hsueh KC, Billing CB Jr, et al. A randomized, placebo-controlled trial of varenicline, a selective alpha4beta2 nicotinic acetylcholine receptor partial agonist, as a new therapy for smoking cessation in Asian smokers. Clin Ther 2007;29:1027-39. https://doi.org/10.1016/j.clinthera.2007.06.011
  6. Cahill K, Stead LF, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev 2012;4:CD006103.
  7. Jung JW, Jeon EJ, Kim JG, Yang SY, Choi JC, Shin JW, et al. Clinical experience of varenicline for smoking cessation. Clin Respir J 2010;4:215-21. https://doi.org/10.1111/j.1752-699X.2009.00178.x
  8. Steinberg MB, Schmelzer AC, Richardson DL, Foulds J. The case for treating tobacco dependence as a chronic disease. Ann Intern Med 2008;148:554-6. https://doi.org/10.7326/0003-4819-148-7-200804010-00012
  9. Hajek P, Stead LF, West R, Jarvis M, Lancaster T. Relapse prevention interventions for smoking cessation. Cochrane Database Syst Rev 2009;(1):CD003999.
  10. Aubin HJ, Bobak A, Britton JR, Oncken C, Billing CB Jr, Gong J, et al. Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trial. Thorax 2008;63:717-24. https://doi.org/10.1136/thx.2007.090647
  11. Nides M, Oncken C, Gonzales D, Rennard S, Watsky EJ, Anziano R, et al. Smoking cessation with varenicline, a selective alpha4beta2 nicotinic receptor partial agonist: results from a 7-week, randomized, placebo- and bupropion-controlled trial with 1-year follow-up. Arch Intern Med 2006;166:1561-8. https://doi.org/10.1001/archinte.166.15.1561
  12. Hsueh KC, Hsueh SC, Chou MY, Pan LF, Tu MS, McEwen A, et al. Varenicline versus transdermal nicotine patch: a 3-year follow-up in a smoking cessation clinic in Taiwan. Psychopharmacology (Berl) 2014;231:2819-23. https://doi.org/10.1007/s00213-014-3482-9
  13. Yilmazel Ucar E, Araz O, Yilmaz N, Akgun M, Meral M, Kaynar H, et al. Effectiveness of pharmacologic therapies on smoking cessation success: three years results of a smoking cessation clinic. Multidiscip Respir Med 2014;9:9. https://doi.org/10.1186/2049-6958-9-9
  14. Anthonisen NR, Connett JE, Kiley JP, Altose MD, Bailey WC, Buist AS, et al. Effects of smoking intervention and the use of an inhaled anticholinergic bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994;272:1497-505. https://doi.org/10.1001/jama.1994.03520190043033
  15. Stapleton JA, Sutherland G, Russell MA. How much does relapse after one year erode effectiveness of smoking cessation treatments? Long-term follow up of randomised trial of nicotine nasal spray. BMJ 1998;316:830-1. https://doi.org/10.1136/bmj.316.7134.830
  16. Fu SS, Partin MR, Snyder A, An LC, Nelson DB, Clothier B, et al. Promoting repeat tobacco dependence treatment: are relapsed smokers interested? Am J Manag Care 2006;12:235-43.
  17. Rigotti NA. Clinical practice. Treatment of tobacco use and dependence. N Engl J Med 2002;346:506-12. https://doi.org/10.1056/NEJMcp012279

피인용 문헌

  1. Results of Smoking Cessation Outpatient Treatment and Examination of Long-term Continuation of Smoking Cessation vol.42, pp.4, 2019, https://doi.org/10.14442/generalist.42.198